913 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Integrity Alliance LLC.

Key Points

• Integrity Alliance LLC made a new investment of approximately $579,000 in Regeneron Pharmaceuticals, Inc., acquiring 913 shares during the first quarter.
• Regeneron Pharmaceuticals experienced a 1.4% decline in stock price, opening at $560.00, despite a strong quarterly earnings report with an EPS of $12.89 against consensus estimates of $8.43.
• The company declared a $0.88 quarterly dividend, with a current payout ratio of 8.87% and an annualized yield of 0.6%.

Integrity Alliance LLC. acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 913 shares of the biopharmaceutical company's stock, valued at approximately $579,000.

Several other large investors also recently bought and sold shares of REGN. GAMMA Investing LLC grew its position in Regeneron Pharmaceuticals by 89,825.0% during the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after purchasing an additional 814,713 shares during the last quarter. Nuveen LLC purchased a new position in Regeneron Pharmaceuticals in the first quarter valued at $343,764,000. Pacer Advisors Inc. increased its holdings in Regeneron Pharmaceuticals by 2,296.9% in the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock worth $258,366,000 after acquiring an additional 390,374 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in Regeneron Pharmaceuticals by 171.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock worth $305,311,000 after buying an additional 303,785 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Regeneron Pharmaceuticals by 30.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock worth $699,554,000 after purchasing an additional 226,952 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on REGN. Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a "moderate buy" rating in a report on Tuesday, September 2nd. Jefferies Financial Group increased their price target on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a research report on Wednesday, August 27th. Rothschild & Co Redburn initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They issued a "buy" rating and a $890.00 price target for the company. Canaccord Genuity Group reiterated a "buy" rating and issued a $850.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Finally, Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 target price on the stock. in a research report on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $817.67.

Regeneron Pharmaceuticals Trading Up 0.4%

REGN traded up $2.47 during midday trading on Tuesday, hitting $575.06. The company's stock had a trading volume of 707,913 shares, compared to its average volume of 1,094,070. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,165.85. The firm has a 50-day moving average price of $565.30 and a two-hundred day moving average price of $577.02. The firm has a market cap of $60.95 billion, a P/E ratio of 14.49, a PEG ratio of 1.87 and a beta of 0.35. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. The business had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company's revenue was up 3.6% compared to the same quarter last year. During the same period in the previous year, the company posted $11.56 EPS. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were paid a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.